Incyte Genomics, Inc. (INCY) Posts Narrower than Expected Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts INCY Hot Sheet
Price: $115.71 -1.04%
EPS Growth %: -256.2%
Financial Fact:
Research and development: 143.18M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: -256.2%
Financial Fact:
Research and development: 143.18M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Incyte Genomics, Inc. (NASDAQ: INCY) reported Q3 loss of ($0.42), $0.03 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $16.8 million versus the consensus estimate of $16.54 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Assumes Incyte (INCY) at Equalweight
- First Citizens Bancshares (FCNCA) reported Q3 EPS
- Balchem Corp. (BCPC) Tops Q3 EPS by 14c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
